Fibromiyalji sendromundaki uyku bozuklukları üzerine trazodonun etkisi
Küçük Resim Yok
Tarih
1998
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu çalışmada fibromiyalji sendromunda (FMS) sık görülen ve etiyolojisinde suçlanan uyku bozukluklarının tedavisinde trazodonun etkinliğinin araştırılması hedef alındı. Yöntem: Uyku kalitesini ölçmek için Pittsburgh Uyku Kalitesi İndeksi (PUKİ) kullanıldı. Cinsiyet, yaş ve tedavi öncesi PUKİ değerleri açısından homojen olan 27 hastaya trazodon (50 mg/gün), 14 hastaya plasebo 3 hafta süreyle verildi. Kontrol PUKl değerlerindeki değişiklikler nonparametrik testlerle değerlendirildi. Bulgular: Trazodon ve plasebo grubunda başlangıç değerlerine göre uyku kalitesinin anlamlı derecede düzeldiği, plasebo grubuna göre trazodon grubundaki düşmenin anlamlı derecede daha fazla, kontrol PUKİ değerlerinin daha düşük olduğu bulundu. Sonuç: FMS'de özellikle uyku kalitesi şikayetleri üzerine trazodon plaseboya göre daha etkilidir.
Objective: This study was performed to investigate the effectiveness of trazodone in the treatment of sleep problems which were frequently seen with and blamed in the etiology of fibromyalgia syndrome (FMS). Methods: Pittsburgh Sleep Quality Inventory (PSQI) was used to assess the sleep quality of patients. Two groups (trazodone, n27; placebo, n14) matched with sex, age and initial PSQI scores were treated for 3 weeks. Trazodone was given 50 mg/day. Nonparametric tests were utilized to analyze the PSQI differences with treatment. Results: There was significant improvement in sleep quality both with trazodone and with placebo group, but the improvement was significantly higher with trazodone than with placebo, and after treatment PSQI scores was low with trazodone. Conclusion: Trazodone is more efficient than placebo, especially on sleep quality of patients with FMS.
Objective: This study was performed to investigate the effectiveness of trazodone in the treatment of sleep problems which were frequently seen with and blamed in the etiology of fibromyalgia syndrome (FMS). Methods: Pittsburgh Sleep Quality Inventory (PSQI) was used to assess the sleep quality of patients. Two groups (trazodone, n27; placebo, n14) matched with sex, age and initial PSQI scores were treated for 3 weeks. Trazodone was given 50 mg/day. Nonparametric tests were utilized to analyze the PSQI differences with treatment. Results: There was significant improvement in sleep quality both with trazodone and with placebo group, but the improvement was significantly higher with trazodone than with placebo, and after treatment PSQI scores was low with trazodone. Conclusion: Trazodone is more efficient than placebo, especially on sleep quality of patients with FMS.
Açıklama
Anahtar Kelimeler
Genel ve Dahili Tıp
Kaynak
Genel Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
8
Sayı
1
